Great Valley Advisor Group Inc. Lowers Stake in Eli Lilly and Company $LLY

Great Valley Advisor Group Inc. lowered its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 23.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,937 shares of the company’s stock after selling 5,429 shares during the period. Great Valley Advisor Group Inc.’s holdings in Eli Lilly and Company were worth $13,983,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Brighton Jones LLC boosted its position in shares of Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after purchasing an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC raised its stake in Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after buying an additional 40 shares during the last quarter. Kaufman Rossin Wealth LLC bought a new stake in Eli Lilly and Company in the first quarter worth $242,000. Horizon Investments LLC grew its stake in shares of Eli Lilly and Company by 6.3% in the first quarter. Horizon Investments LLC now owns 9,491 shares of the company’s stock worth $7,839,000 after acquiring an additional 559 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Eli Lilly and Company by 2.5% during the first quarter. Dimensional Fund Advisors LP now owns 3,796,285 shares of the company’s stock valued at $3,135,290,000 after acquiring an additional 94,078 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

LLY has been the topic of a number of analyst reports. CICC Research upped their price target on shares of Eli Lilly and Company from $801.00 to $1,060.00 and gave the stock a “neutral” rating in a research note on Thursday, November 13th. Guggenheim reiterated a “buy” rating and issued a $1,163.00 target price on shares of Eli Lilly and Company in a research note on Wednesday, December 3rd. Sanford C. Bernstein increased their price target on shares of Eli Lilly and Company from $1,100.00 to $1,300.00 and gave the company an “outperform” rating in a report on Monday, November 24th. Weiss Ratings restated a “buy (b-)” rating on shares of Eli Lilly and Company in a report on Tuesday. Finally, Hsbc Global Res raised Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,109.24.

Eli Lilly and Company Stock Up 1.8%

LLY opened at $1,027.68 on Friday. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The firm has a 50 day moving average price of $939.47 and a 200-day moving average price of $818.98. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,111.99. The stock has a market capitalization of $971.55 billion, a price-to-earnings ratio of 50.28, a PEG ratio of 1.12 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The company had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. During the same quarter last year, the company posted $1.18 earnings per share. The firm’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a $1.73 dividend. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio (DPR) is 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.